pyrazines has been researched along with fibrinogen in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, SF; Peng, W | 1 |
| Fujisawa, Y; Fukushi, H; Imai, Y; Kawamura, M; Kita, S; Miyawaki, T; Sugihara, H; Terashita, Z | 1 |
| Corral, J; de Arriba, F; Ferrer, F; González, M; Hernández-Espinosa, D; Martínez, C; Miñano, A; Mota, RA; Ordoñez, A; Pérez-Ceballos, E; Vicente, V | 1 |
| Affeld, K; Dohmen, PM; Kertzscher, U; Konertz, W; Linneweber, J | 1 |
| Björkman, JA; Jones, HB; Schofield, J | 1 |
1 trial(s) available for pyrazines and fibrinogen
| Article | Year |
|---|---|
Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.
Topics: Alleles; alpha 1-Antitrypsin; Animals; Antineoplastic Agents; Antithrombins; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Endoplasmic Reticulum; Factor Xa Inhibitors; Fibrinogen; Humans; Immunohistochemistry; Injections, Intravenous; Leukocyte Elastase; Liver; Liver Neoplasms; Male; Mice; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Proteins; Pyrazines; Serpins; Ubiquitin | 2008 |
4 other study(ies) available for pyrazines and fibrinogen
| Article | Year |
|---|---|
[Effect of ligustrazine controlled release capsule on hemorrheology in patients with cor pulmonale].
Topics: 6-Ketoprostaglandin F1 alpha; Aged; Blood Viscosity; Delayed-Action Preparations; Female; Fibrinogen; Hematocrit; Humans; Male; Middle Aged; Pulmonary Heart Disease; Pyrazines; Thromboxane B2 | 1993 |
Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
Topics: Animals; Drug Design; Fibrinogen; Guanidines; Guinea Pigs; Humans; In Vitro Techniques; Kinetics; Molecular Structure; Oligopeptides; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazines; Structure-Activity Relationship | 1998 |
Local glycoprotein IIb/IIIa receptor inhibitor delivery from the pump surface attenuates platelet adhesion in continuous flow ventricular assist devices.
Topics: Adsorption; Blood Platelets; Delayed-Action Preparations; Fibrinogen; Guanidines; Heart-Assist Devices; Hemorheology; Humans; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrazines | 2008 |
Coronary and systemic arterial physiology and immunohistochemical markers related to early coronary arterial lesions in beagle dogs given the potassium channel opener, ZD6169, or the endothelin receptor antagonist, ZD1611.
Topics: Amides; Animals; Arteritis; Benzophenones; Biomarkers; Blood Pressure; Coronary Vessels; Dogs; Electrocardiography; Female; Fibrinogen; Heart; Heart Rate; Immunohistochemistry; Myocardium; Pyrazines; Sulfonamides; von Willebrand Factor | 2013 |